Abstract:Objective To explore the effects of aggressive lipid lowering therapy and its influence on cardiovascular events using lipitor(20 mg daily)for Chinese people after percutaneous coronary intervention(PCI). Methods We did a double-blind and randomized controlled trial.From July 2005 to June 2006,120 patients with PCI procedure who were discharged from the Shanghai Chest Hospital were randomly divided into aggressive lipid lowering group(atorvastatin 20 mg daily,n=60)and an ordinary lipid lowering group(atorvastatin 10 mg daily,n=60).The trial treatment was administered from the day of PCI to the third month after PCI.Atorvastatin at 10 mg daily was then used until one year after PCI.Blood biochemistry,cardiovascular events and drug adverse reactions were compared between the two groups.Results Among the 120 patients,5 discontinued treatment and 4 more withdrew from the study.Therefore 115 and 111 were included in our main analyses[Comment from Mike:it is not ITT if the 5 who discontinued treatment are excluded] and a per-protocol(PP)analysis,respectively. Baseline clinical characteristics were comparable between the two groups.The reduction in TG and the increase in HDL-C were similar between the two groups(P＞0.05),but the reductions in LDL-C and TC were significantly different between the two groups(P＜0.05).This was observed from the beginning of follow-up to the third month after PCI.In the PP analysis,the percentage of patients whose LDL-C met the predefined requirement at the third month in the 20 mg group was significantly higher than in the group receiving the lower dose(87.03% vs.70.17%,P=0.031).A similar result was also obtained if the patients who withdrew were retained in the analysis(P=0.044).The change in C reaction protein(CRP)from baseline at the first and the third month was significantly different between the two groups(P＜0.05), but become relatively stable at the sixth month(P＞0.05).The mean follow-up duration was 6.5±3.0 months in the higher dose group,with 1 case of recurring angina pectoris and 1 case of revascularization were identified.It was 7.2±3.6 months in the 10 mg daily group,with 3 cases of recurring angina pectoris,1 case of nonfatal myocardial infarction,2 cases of revascularization and 1 case of sudden cardiogenic death.The difference in the Kaplan-Meier event curves was of borderline statistical significance from the fourth month(P=0.048).Drug adverse reactions were mild and myopathy was not identified in any patients.Conclusions After PCI procedure,the use of atorvastatin 20 mg daily for aggressive lipid lowering was safe and effective.

Impacts of serum P-selectin on blood pressure control after PCI in patients with coronary heart disease complicated with hypertension.

Short term effects of sodium-glucose cotransporter 2 inhibitors on lipid regulation in coronary artery disease patients undergoing Percutaneous Coronary Intervention: A Propensity-Matched Analysis

Effect of P-selectin in primary hypertension associated with lacunar infarction

Temporal Changes in Circulating P-selectin, Plasminogen Activator Inhibitor-1, Magnesium, and Creatine Kinase after Percutaneous Coronary Intervention

Effects of Percutaneous Transluminal Coronary Angioplasty on Serum Soluble Intercellular Adhesion Molecule-1 and P-selectin Levels

Impact of serum lipid level on residual platelet reactivity in patients with non-ST elevation acute coronary syndrome receiving dual anti-platelet therapy after percutaneous coronary intervention

Changes of Plasma P-selectin、 Thrombomodulin、 Plasminogen Activator Inhibitor-1 of Coronary Artery Disease Patients Before and after PTCA

Efficacy and Safety of Serial Atorvastatin Load in Chinese Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the ISCAP (intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) Randomized Controlled Trial

Changes and Clinical Significance of P-selectin and Yon Willebrand Factor in Patients with Coronary Heart Disease

Clinical Significance of PCSK9 and Soluble P-selectin in Predicting Major Adverse Cardiovascular Events after Primary Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome

The contribution of genotype-guided selection of P2Y12 inhibitor on prognosis in ACS /CCS patients undergoing percutaneous coronary intervention: a retrospective cohort study

A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel

Abstract 119: P2Y12 Inhibitor With Or Without Aspirin In Patients With Hypertension Undergoing Percutaneous Coronary Intervention

Influence of Serum Apelin and CD40L Expression Levels on Adverse Cardiovascular Events after PCI

The Study of the Effect of PTCA on P-selectin,Plasminogen Activator In hibitor-1 and Mg2+ in Peripheral Blood

Long-term effects of baseline on-treatment platelet reactivity in patients with acute coronary syndrome and thrombocytopenia undergoing percutaneous coronary intervention

P-selectin and C-reactive protein in relation to home blood pressure and coronary calcification: a SCAPIS substudy

Change of Level of Platelet Activating Factor after Drug Eluting Stent Implantation in Patients with Stable Coronary Heart Disease and Its Significance

Minor stroke patients with mild-moderate diastolic blood pressure derive greater benefit from dual antiplatelet therapy

The Contribution of Aggressive Lipid Lowering by Lipitor to Cardiovascular Events after Percutaneous Coronary Intervention

Elevated High-Sensitivity C-Reactive Protein Level Enhances the Impact of Lipoprotein(a) on Platelet Reactivity in PCI Patients Treated with Clopidogrel